false
0001726711
0001726711
2024-07-18
2024-07-18
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): July 18, 2024
Aditxt, Inc.
(Exact
name of registrant as specified in its charter)
Delaware |
|
001-39336 |
|
82-3204328 |
(State
or other jurisdiction |
|
(Commission File
Number) |
|
(I.R.S.
Employer |
of
incorporation) |
|
|
|
Identification
No.) |
2569 Wyandotte Street, Suite 101, Mountain View, CA 94043 |
(Address of principal executive
offices, including zip code) |
Registrant’s
telephone number, including area code: (650) 870-1200
Not
Applicable
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of
the following provisions:
☐ |
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Common Stock, par value $0.001 |
|
ADTX |
|
The Nasdaq Stock Market
LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item
1.01. Entry into a Material Definitive Agreement
Arrangement
Agreement
As
previously reported in a Current Report on Form 8-K filed by Aditxt, Inc. (“Aditxt” or the “Company”),
on April 1, 2024 (the “Execution Date”), the Company entered into an Arrangement Agreement (the “Arrangement
Agreement”) with Adivir, Inc., a Delaware corporation and wholly owned subsidiary of the Company (“Adivir”
or the “Buyer”), and Appili Therapeutics, Inc., a Canadian corporation (“Appili”), pursuant to
which, Adivir will acquire all of the issued and outstanding Class A common shares of Appili (the “Appili Shares”)
on the terms and subject to the conditions set forth therein. The acquisition of the Appili Shares (the “Arrangement”)
will be completed by way of a statutory plan of arrangement under the Canada Business Corporation Act (the “CBCA”).
As
previously reported in a Current Report on form 8-K filed by the Company, on July 1, 2024, the Company, Adivir and Appili entered into
an Amending Agreement (the “First Amending Agreement”), pursuant to which the Parties (as defined in the Arrangement
Agreement) agreed that: (i) the Outside Date (as defined in the Arrangement Agreement) would be changed to August 30, 2024; (ii) the
date by which Appili shall convene and conduct the stockholder meeting to approve the Arrangement Agreement (the “Appili Meeting”)
would be no later than August 30, 2024, provided that Appili shall be under no obligation to convene the Appili Meeting prior to the
date that is 50 days following the date that Aditxt delivers to Appili all complete Additional Financial Disclosure (as defined in the
Arrangement Agreement) required for inclusion in the circular; (iii) Aditxt shall use commercially reasonable efforts to complete the
Financing (as defined in the Arrangement Agreement) no later than August 30, 2024; and (iv) Aditxt or Appili may terminate the Arrangement
Agreement if the Financing is not completed by 5:00 p.m. (ET) on August 30, 2024 or such later date as the Parties may agree in writing.
On
July 18, 2024, the Company, Adivir and Appili entered into a Second Amending Agreement (the “Second Amending Agreement”),
pursuant to which the Arrangement Agreement was amended to provide that (i) the Outside Date will be extended to September 30, 2024,
(ii) the Appili Meeting will be conducted no later than September 30, 2024, provided that Appili shall be under no obligation to hold
the Appili Meting prior to the date that is 50 days following the date that the Company delivers all complete Additional Financial Disclosure
required for inclusion in the circular; (iii) the Company shall use commercially reasonable efforts to complete the Financing on or prior
to September 15, 2024; and (iv) the Company and Appili may terminate the Arrangement Agreement if the Financing is not completed on or
before 5:00 p.m. (ET) on September 15, 2024 or such later date as the Parties may in writing agree
A
copy of the Second Amending Agreement is filed with this Current Report on Form 8-K as Exhibit 2.1 and is incorporated herein
by reference. The foregoing description of the Second Amending Agreement and the transactions contemplated thereby is incomplete and
is subject to, and qualified in its entirety by, reference to the actual agreement. The Second Amending Agreement and other agreements
described above have been included as exhibits to this Current Report on Form 8-K and the current Reports on Form 8-K referenced above
to provide security holders with information regarding their terms. It is not intended to provide any other factual information about
the Company, Adivir or Appili. In particular, the assertions embodied in representations and warranties by the Company, Adivir and Appili
contained in the Arrangement Agreement, as amended to date, were made as of a specified date, are subject to important qualifications
and limitations agreed to by the parties in connection with negotiating such agreement, including being qualified by confidential information
in the disclosure letters provided by the parties in connection with the execution of the Arrangement Agreement, and are subject to standards
of materiality applicable to the contractive parties that may differ from those applicable to security holders. The confidential disclosures
contain information that modifies, qualifies and creates exceptions to the representations and warranties set forth in the Arrangement
Agreement. Moreover, certain representations and warranties in the Arrangement Agreement were used for the purpose of allocating risk
between the parties, rather than establishing matters as facts. Accordingly, security holders should not rely on the representations
and warranties in the Arrangement Agreement as characterizations of the actual state of facts about the Company, Adivir or Appili. Moreover,
information concerning the subject matter of the representations and warranties may change after the date of the Arrangement Agreement,
which subsequent information may or may not be fully reflected in the Company’s public disclosures.
Cautionary
Note on Forward-Looking Statements
This
Current Report on Form 8-K contains certain forward-looking statements within the meaning of the “safe harbor “provisions
under the United States Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained
in this Current Report on Form 8-K, including statements regarding the Company’s or Appili’s future results of operations
and financial position are forward-looking statements. These forward-looking statements generally are identified by the words “believe,”
“project,” “expect,” “anticipate,” “estimate,” “target,” “intend,”
“strategy,” “future,” “opportunity,” “plan,” “may,” “should,”
“will,” “would,” “will be,” “will continue,” “will likely result,” and similar
expressions. These statements are based on various assumptions, whether or not identified in this Current Report on Form 8-K, and on
the current expectations of the respective management teams of the Company and Appili and are not predictions of actual performance.
These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied
on by an investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances
are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control
of the Company and Appili.
These
forward-looking statements are subject to a number of risks including, but not limited to, the following risks relating to the proposed
transactions: (1) the risk that the proposed transactions may not be completed in a timely manner or at all, which may adversely affect
the price of the Company’s securities; (2) the failure to satisfy the conditions to the Closing, including the approval by the
shareholders of Appili and the completion of the Financing by the Company; (3) the ability to realize the anticipated benefits of the
proposed transactions; and (4) other risks and uncertainties indicated from time to time in the Company’s public filings with the
SEC. If any of these risks materialize or the Company’s and Appili’s assumptions prove incorrect, actual results could differ
materially from the results implied by these forward-looking statements. You should carefully consider the risks and uncertainties described
in the “Risk Factors” section of our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 and other documents
we filed, or will file with the SEC. There may be additional risks that neither the Company nor Appili presently know, or that the Company
or Appili currently believe are immaterial, that could also cause actual results to differ from those contained in the forward-looking
statements. In addition, forward-looking statements reflect the Company’s and Appili’s expectations, plans or forecasts of
future events and views as of the date of this Current Report on Form 8-K. The Company and Appili anticipate that subsequent events and
developments will cause the Company’s and Appili’s assessments to change. However, while the Company and Appili may elect
to update these forward-looking statements at some point in the future, the Company and Appili specifically disclaim any obligation to
do so, except as otherwise required by law. These forward-looking statements should not be relied upon as representing the Company’s
and Appili’s assessments of any date subsequent to the date of this Current Report on Form 8-K. Accordingly, undue reliance should
not be placed upon the forward-looking statements.
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits.
| † | Certain
of the schedules (and/or exhibits) have been omitted pursuant to Item 601(b)(2) of Regulation S-K. A copy of any omitted schedule (and/or
exhibit) will be furnished to the SEC upon request |
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
Aditxt, Inc. |
|
|
|
Date: July 22, 2024 |
By: |
/s/ Amro
Albanna |
|
Name: |
Amro Albanna |
|
Title: |
Chief Executive Officer |
-3-
Exhibit 2.1
SECOND AMENDING AGREEMENT
THIS SECOND AMENDING AGREEMENT
is made as of July 18, 2024,
BETWEEN:
Appili Therapeutics Inc., a corporation
existing under the laws of Canada
(the “Company”)
- and –
Aditxt, Inc., a corporation existing
under the laws of the State of Delaware
(the “Parent”)
- and –
Adivir, Inc., a corporation existing
under the laws of the State of Delaware
(the “Buyer”)
(collectively referred to as the “Parties”,
and each individually as a “Party”)
WHEREAS:
| A. | The Parties entered into an arrangement agreement dated April 1, 2024 (as amended on July 1, 2024, the
“Arrangement Agreement”) pursuant to which, among other things, the Parent, through its wholly-owned subsidiary, the
Buyer, has agreed to acquire all of the issued and outstanding Company Shares on the terms set forth in the Arrangement Agreement pursuant
to an arrangement under the provisions of the Canada Business Corporations Act; |
| B. | The Parties wish to enter into this amending agreement (this “Amending Agreement”)
to amend certain terms of the Arrangement Agreement. All capitalized terms used herein but not defined herein shall have their respective
meanings set forth in the Arrangement Agreement. |
NOW THEREFORE in consideration of the premises
and the mutual agreements and covenants herein contained and other good and valuable consideration (the receipt and adequacy of which
is hereby acknowledged), the Parties hereto hereby covenant and agree as follows:
| 1. | The definition of “Outside Date” in Section 1.01 of the Arrangement Agreement shall be deleted
in its entirety and replaced with the following: |
“Outside Date”
means September 30, 2024.”
| 2. | Section 2.06(a) of the Arrangement Agreement Agreement shall be deleted in its entirety and replaced with
the following: |
“convene and
conduct the Company Meeting in accordance with the Interim Order, the Company’s constating documents and applicable Laws as promptly
as practicable (and in any event the Company will use commercially reasonable efforts to do so not later than September 30, 2024, provided
that the Company shall be under no obligation to hold the Company Meeting prior to the date that is 50 days following the date that the
Parent delivers to the Company all complete Additional Financial Disclosure required for inclusion in the Company Circular as contemplated
by Section 5.02(c)(v), and in this regard, the Company may abridge any time periods that may be abridged under Securities Laws for the
purpose of considering the Arrangement Resolution and for any other purposes as may be set out in the Company Circular and agreed to by
the Parent in writing, acting reasonably; set, publish and give notice of, the record date for the Company Shareholders entitled to vote
at the Company Meeting as promptly as reasonably practicable; and not adjourn, postpone or cancel (or propose the adjournment, postponement
or cancellation of) the Company Meeting without the prior written consent of the Parent (such consent not to be unreasonably withheld,
conditioned or delayed), except as required or permitted under Section 6.04 or Section 7.03(b) or as required for quorum purposes (in
which case, the Company Meeting shall be adjourned and not cancelled) or as required by applicable Laws or a Governmental Entity. Notwithstanding
the foregoing, the Company may further extend the time of the Company Meeting in the event that any auditor consent (or similar instrument)
is required with respect to the Additional Financing Disclosure and such consent (or similar instrument) is not available at the scheduled
time of printing the Company Circular – such extended period of time to be agreed to by the Company and the Parent, each acting
reasonably.”
| 3. | Section 5.03(e) of the Arrangement Agreement shall be deleted in its entirety and replaced with the following: |
“The Parent
shall use commercially reasonable efforts to complete the Financing on or prior to 5:00 p.m. (ET) on September 15, 2024 and reserve such
appropriate amount of proceeds of the Financing to fulfill its obligations contemplated herein.”
| 4. | Section 8.02(d) of the Arrangement Agreement shall be deleted in its entirety and replaced with the following: |
“the Financing
is not completed on or before 5:00 p.m. (ET) on September 15, 2024 or such later date as the Parties may in writing agree.”
| 5. | This Amending Agreement shall be binding upon and enure to the benefit of the Company, the Parent, the
Buyer and their respective successors and permitted assigns. |
| 6. | This Agreement shall be construed and interpreted in accordance with the laws of the Province of Ontario
and federal laws of Canada applicable therein. |
| 7. | This Amending Agreement may be executed by facsimile or other electronic signature and in counterparts,
each of which shall be deemed an original, and all of which together constitute one and the same instrument. |
| 8. | This Amending Agreement is supplementary to the Arrangement Agreement and is to be read with and construed
in accordance with the Arrangement Agreement as if this Amending Agreement and the Arrangement Agreement constitute one agreement. |
| 9. | Other than as provided in this Amending Agreement, all other terms and conditions of the Arrangement Agreement,
as amended, shall remain in full force and effect, unamended, and the Parties hereto hereby ratify and confirm the same. |
[remainder of this page
intentionally left blank]
IN WITNESS WHEREOF,
the Parties have executed this Amending Agreement as of the date first written above.
|
APPILI THERAPEUTICS INC. |
|
|
|
By: |
/s/ Don Cilla |
|
|
Name: |
Don Cilla |
|
|
Title: |
President and Chief Executive Officer |
|
ADITXT, INC. |
|
|
|
By: |
/s/ Amro Albanna |
|
|
Name: |
Amro Albanna |
|
|
Title: |
Chief Executive Officer |
|
ADIVIR, INC. |
|
|
|
By: |
/s/ Amro Albanna |
|
|
Name: |
Amro Albanna |
|
|
Title: |
Authorized Signatory |
[Signature
Page to the Second Amending Agreement]
3
v3.24.2
Cover
|
Jul. 18, 2024 |
Cover [Abstract] |
|
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Jul. 18, 2024
|
Entity File Number |
001-39336
|
Entity Registrant Name |
Aditxt, Inc.
|
Entity Central Index Key |
0001726711
|
Entity Tax Identification Number |
82-3204328
|
Entity Incorporation, State or Country Code |
DE
|
Entity Address, Address Line One |
2569 Wyandotte Street
|
Entity Address, Address Line Two |
Suite 101
|
Entity Address, City or Town |
Mountain View
|
Entity Address, State or Province |
CA
|
Entity Address, Postal Zip Code |
94043
|
City Area Code |
650
|
Local Phone Number |
870-1200
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Title of 12(b) Security |
Common Stock, par value $0.001
|
Trading Symbol |
ADTX
|
Security Exchange Name |
NASDAQ
|
Entity Emerging Growth Company |
true
|
Elected Not To Use the Extended Transition Period |
false
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14a -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Aditxt (NASDAQ:ADTX)
Historical Stock Chart
From Jul 2024 to Aug 2024
Aditxt (NASDAQ:ADTX)
Historical Stock Chart
From Aug 2023 to Aug 2024